Inso Biosciences

InSyBio is a global biotechnology company meeting the needs of molecular biology researchers in the academia, private research sector and pharmaceutical companies. For this reason, we are striving for the continuous production of intelligent and innovative algorithms to assist our customers in inferring knowledge from experimental data. Being a young company, InSyBio aspires to contribute to the development of the globalized orientation of entrepreneurship through its association and cooperation with academic, research and business organizations worldwide. At InSyBio, we are passionate about supporting our customers to minimize their efforts, as they design and develop new drugs, nutritional products, therapeutic and diagnostic methods. Offering tools for biomarker discovery, biological data management, secured storage and computational bio-data analysis, our mission is to accelerate preclinical and clinical studies of pharmaceutical companies as well as to provide precise solutions for biomarker discovery in nutrition industry, biotechnology industry and academia. Dietary and nutritional products affect individuals differently based on their genetic predisposition, nutritional lifestyle, exercises habits, and their environments. Publishing scientific findings in domain-specific journals and announcing them in scientific conferences has become an essential part of today’s research environment.

InBios is a leading biotechnology company based in Seattle, Washington (USA). At InBios, we believe an accurate diagnosis is the first step to effective treatment. InBios has a long history of market leadership. InBios also specializes in the development and manufacture of highly specific and well-characterized antibodies and antigens for use in infectious disease research. InBios is GMP compliant, FDA registered, USDA licensed and ISO 13485:2016 certified. InBios is a total solution company with expertise in all facets of the product pipeline, from discovery to application. From concept to clinic, InBios partners with private companies, federal laboratories and academia to bring our customers the best scientific solutions for their diagnostic needs. InBios Awarded New Contract to Supply COVID-19 Tests as Part of HHS/ASPR Effort to Strengthen Domestic Supply Chain.

Our proprietary platform for developing and producing complex biologically-active glycans. Inbiose signs €15 million loan with European Investment Bank to scale up its research and development and accelerate market launch of its pr... Inbiose sets a new landmark in its growth.

INanoBio is developing an advanced 3D nanopore – transistor device for sequencing the whole human genome with high accuracy, at one-tenth the current cost and time. INanoBio’s sequencer will enable sequencing genomes of whole populations across the world. INanoBio is developing advanced nano-biotechnology tools that enable discovering of disease specific molecular biomarkers and detecting them in blood with ultra-high sensitivity. We are developing simple blood tests to detect cancers early, obviating the need for biopsy. INanoBio CEO, Bharath Takulapalli will be presenting at the Precision Medicine World Conference 2022 at the Santa Clara Convention Center. INanoBio CEO, Bharath Takulapalli to speak at the MEMS & Sensors Technical Congress to be held at the David Brower Center in Berkeley. Nanopore Sequencing Firm iNanoBio Says Fast Sensor Will Result in Speedy Platform. INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning.

At SBI, our mission is to accelerate your science by turning the latest insights and technologies into robust research products and services to advance exosome studies, biomarker research, gene delivery, SARS-CoV-2 studies, and more. SBI is a small biotech company that’s delivered innovative products and services for molecular and cell biology research since January 2004, when we sold our first lentivectors and pPACK lentivirus packaging systems. We focus on being the first company to bring the newest methodologies to market—we were the first company to deliver exosome research reagents and CRISPR/Cas9 vectors—so researchers can quickly take advantage of the latest, most powerful approaches. Dedicated to quality, many of our products and most of our service offerings are completed in our state-of-the-art facility in Palo Alto CA, enabling us to maintain control over manufacturing conditions and quality, ensure our service projects remain confidential, and deliver frequent and timely service project status updates. Their areas of expertise cover our range of offerings, including exosome research, genome engineering, cell biology, next-generation sequencing (NGS), qPCR microarrays, flow cytometry, and more. We work closely with these collaborators and consultants to ensure that we deliver the very best and very latest technologies solidly grounded in good science. The easiest way to leverage SBI’s highly-regarded gene expression and delivery technologies. Enjoy consistent quality, confidentiality, and on-time delivery with all projects completed on-site in our Palo Alto, CA, facility.

We are committed to advancing the scientific understanding of complex therapeutic areas like Oncology, Immunology, Neurology, Infectious Disease, Regenerative Medicine, and the application areas like Microbiology, Genomics, Proteomics, Spatial Omics, Metabolomics, Polymers Analysis, and many more. We are proud of what we do as well as how we take care of the clients. We profusely thank BIOINNOVATIONS for assistance in the whole-genome sequence analysis. As a leader in the industry since 2010, We have an association with technology leaders for Clinical, Analytical, and Life Sciences requirements. We work to promote a healthier world by enabling our customers to deliver innovative technologies with a comprehensive portfolio from detection and imaging solutions to informatics and services. Honesty is the base of everything we do. Our core values define our business culture and who we are as BIOINNOVATIONS employees. To create a sustainable and high-value health system with Bioinnovations.